{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:07:29Z","timestamp":1794276449224,"version":"4.9.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021771","name":"Student Research Committee, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["71909"],"award-info":[{"award-number":["71909"]}],"id":[{"id":"10.13039\/501100021771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021771","name":"Student Research Committee, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["CRD42023441625"],"award-info":[{"award-number":["CRD42023441625"]}],"id":[{"id":"10.13039\/501100021771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.msard.2024.105530","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T16:48:21Z","timestamp":1709225301000},"page":"105530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Serum lipids and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"given":"Sarvin","family":"Sanaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Koohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mosaddeghi-Heris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Movagharnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanie","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedehyasmin","family":"Moghaddamziabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Hamzehzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Gholipour-khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-0109","authenticated-orcid":false,"given":"Amirreza","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2024.105530_bib0001","first-page":"e18092","article-title":"The effectiveness of statins as potential therapy for multiple sclerosis: a systematic review of randomized controlled trials","volume":"13","author":"Abdalla","year":"2021","journal-title":"Cureus."},{"key":"10.1016\/j.msard.2024.105530_bib0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4020-8831-5_9","article-title":"Altered lipid metabolism in brain injury and disorders","volume":"49","author":"Adibhatla","year":"2008","journal-title":"SubCell Biochem."},{"issue":"4","key":"10.1016\/j.msard.2024.105530_bib0003","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10787-023-01240-x","article-title":"The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects","volume":"31","author":"Al-Kuraishy","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"5","key":"10.1016\/j.msard.2024.105530_bib0004","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/1352458516686847","article-title":"Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop","volume":"24","author":"Amato","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/00207454.2020.1807980","article-title":"Is there a correlation between dyslipidemia and cognitive impairment in patients with multiple sclerosis?","volume":"132","author":"Andaloro","year":"2021","journal-title":"Int. J. Neurosci."},{"issue":"4","key":"10.1016\/j.msard.2024.105530_bib0006","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1355617706060723","article-title":"Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)","volume":"12","author":"Benedict","year":"2006","journal-title":"J. Int. Neuropsychol. Soc."},{"issue":"8","key":"10.1016\/j.msard.2024.105530_bib0007","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/jnnp-2013-307106","article-title":"Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes","volume":"85","author":"Browne","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9936","key":"10.1016\/j.msard.2024.105530_bib0008","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105530_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104397","article-title":"Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis","volume":"68","author":"Coll-Martinez","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2024.105530_bib0010","doi-asserted-by":"crossref","first-page":"e2405","DOI":"10.1002\/brb3.2405","article-title":"Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis","volume":"11","author":"Coll-Martinez","year":"2021","journal-title":"Brain Behav."},{"issue":"10","key":"10.1016\/j.msard.2024.105530_bib0011","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1007\/s12035-016-0281-9","article-title":"Reduced plasma levels of 25-hydroxycholesterol and increased cerebrospinal fluid levels of bile acid precursors in multiple sclerosis patients","volume":"54","author":"Crick","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.msard.2024.105530_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1017\/S0317167100014384","article-title":"Value of the MoCA test as a screening instrument in multiple sclerosis","volume":"40","author":"Dagenais","year":"2013","journal-title":"Can. J. Neurol. Sci."},{"issue":"20","key":"10.1016\/j.msard.2024.105530_bib0013","article-title":"Lipid profile in multiple sclerosis: functional capacity and therapeutic potential of its regulation after intervention with epigallocatechin gallate and coconut oil","volume":"12","author":"de la","year":"2023","journal-title":"Foods"},{"issue":"6","key":"10.1016\/j.msard.2024.105530_bib0014","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3233\/JPD-213135","article-title":"Blood lipid biomarkers in early parkinson's disease and parkinson's disease with mild cognitive impairment","volume":"12","author":"Deng","year":"2022","journal-title":"J. Parkinsons. Dis."},{"issue":"12","key":"10.1016\/j.msard.2024.105530_bib0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/00207454.2021.1879066","article-title":"Neurocognitive impairment and social cognition in multiple sclerosis","volume":"132","author":"Doskas","year":"2022","journal-title":"Int. J. Neurosci."},{"issue":"8","key":"10.1016\/j.msard.2024.105530_bib0016","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00415-020-09841-0","article-title":"Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy","volume":"267","author":"Engl","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105530_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102189","article-title":"An overview of lipidomic analysis in different human matrices of multiple sclerosis","volume":"44","author":"Ferreira","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105530_bib0018","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jpba.2019.06.005","article-title":"Lipidomics in autoimmune diseases with main focus on systemic lupus erythematosus","volume":"174","author":"Ferreira","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"10.1016\/j.msard.2024.105530_bib0019","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/1352458515593637","article-title":"Brief international cognitive assessment for multiple sclerosis (BICAMS) and performance of everyday life tasks: actual reality","volume":"22","author":"Goverover","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.msard.2024.105530_bib0020","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.bbi.2010.05.006","article-title":"Correlates of cognitive dysfunction in multiple sclerosis","volume":"24","author":"Heesen","year":"2010","journal-title":"Brain Behav. Immun."},{"issue":"12","key":"10.1016\/j.msard.2024.105530_bib0021","doi-asserted-by":"crossref","first-page":"9667","DOI":"10.1007\/s11033-020-06011-3","article-title":"Lipid profile: causal relationship on cognitive performance in multiple sclerosis?","volume":"47","author":"Hern\u00e1ndez-Ledesma","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0022","first-page":"206","article-title":"Smoking, cardiovascular risk factors and LRP2 gene variation: associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis","volume":"27","author":"Hoejsgaard Chow","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0023","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1352458518819608","article-title":"Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients","volume":"26","author":"Jakimovski","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0024","first-page":"181","article-title":"Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis","volume":"87","author":"Kappus","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2024.105530_bib0025","doi-asserted-by":"crossref","first-page":"e13300","DOI":"10.1111\/ijcp.13300","article-title":"Assessment and management of cognitive problems in people with multiple sclerosis: a national survey of clinical practice","volume":"73","author":"Klein","year":"2019","journal-title":"Int. J. Clin. Pract."},{"issue":"11","key":"10.1016\/j.msard.2024.105530_bib0026","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","article-title":"Apparent changes in the epidemiology and severity of multiple sclerosis","volume":"17","author":"Koch-Henriksen","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0027","first-page":"75","article-title":"How much is the cost of multiple sclerosis--systematic literature review","volume":"67","author":"Kolasa","year":"2013","journal-title":"Przegl. Epidemiol."},{"issue":"6","key":"10.1016\/j.msard.2024.105530_bib0028","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s10072-020-04847-y","article-title":"Impact of chemerin, lipid profile, and insulin resistance on disease parameters in patients with multiple sclerosis","volume":"42","author":"Koskderelioglu","year":"2021","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2024.105530_bib0029","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS)","volume":"18","author":"Langdon","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2024.105530_bib0030","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/1352458515611222","article-title":"No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon \u03b21b therapy in relapsing\u2013remitting multiple sclerosis (the ARIANNA study)","volume":"22","author":"Lanzillo","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"10","key":"10.1016\/j.msard.2024.105530_bib0031","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.molmed.2010.07.008","article-title":"APOE and cholesterol homeostasis in alzheimer's disease","volume":"16","author":"Leduc","year":"2010","journal-title":"Trends. Mol. Med."},{"issue":"22","key":"10.1016\/j.msard.2024.105530_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10225405","article-title":"Association between serum lipid parameters and cognitive performance in older adults","volume":"10","author":"Lee","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0033","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/med.21534","article-title":"Involvement of calpain in the neuropathogenesis of Alzheimer's disease","volume":"39","author":"Mahaman","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"10","key":"10.1016\/j.msard.2024.105530_bib0034","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00228-022-03363-6","article-title":"Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews","volume":"78","author":"Majidazar","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0035","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10072-021-05383-z","article-title":"ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study","volume":"43","author":"Mashayekhi","year":"2022","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ncl.2015.08.002","article-title":"Behavioral neurology of multiple sclerosis and autoimmune encephalopathies","volume":"34","author":"Moghadasi","year":"2016","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2024.105530_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102478","article-title":"Pharmacotherapy in multiple sclerosis-induced cognitive impairment: a systematic review and meta-analysis","volume":"46","author":"Motavalli","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0038","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/ene.14055","article-title":"Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up","volume":"27","author":"Murali","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105530_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104011","article-title":"The association of apolipoprotein E (ApoE) genotype and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis","volume":"65","author":"Naseri","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2024.105530_bib0040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1474-4422(04)00770-7","article-title":"Are statins a treatment option for multiple sclerosis?","volume":"3","author":"Neuhaus","year":"2004","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-47906-x","article-title":"Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis","volume":"9","author":"Nogueras","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2024.105530_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101415","article-title":"The correlation between dyslipidemia and cognitive impairment in multiple sclerosis patients","volume":"36","author":"Noori","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.msard.2024.105530_bib0043","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jns.2015.08.1537","article-title":"Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis","volume":"358","author":"Novakova","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2024.105530_bib0044","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2024.105530_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0047","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.brainresrev.2005.11.007","article-title":"Lipid metabolism in cognitive decline and dementia","volume":"51","author":"Panza","year":"2006","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.msard.2024.105530_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105035","article-title":"Molecular biomarkers and cognitive impairment in multiple sclerosis: state of the field, limitations, and future direction - A systematic review and meta-analysis","volume":"146","author":"Rademacher","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.msard.2024.105530_bib0049","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/brainsci11040502","article-title":"A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis","volume":"11","author":"Reia","year":"2021","journal-title":"Brain Sci."},{"issue":"6","key":"10.1016\/j.msard.2024.105530_bib0050","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s13760-020-01509-w","article-title":"Montreal cognitive assessment for evaluating cognitive impairment in multiple sclerosis: a systematic review","volume":"120","author":"Rosca","year":"2020","journal-title":"Acta Neurol. Belg."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0051","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","article-title":"APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches","volume":"20","author":"Serrano-Pozo","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105530_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104374","article-title":"Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis","volume":"69","author":"Siddiqui","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105530_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104370","article-title":"Metabolic syndrome parameters and multiple sclerosis disease outcomes: a portuguese cross-sectional study","volume":"69","author":"Silva","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0054","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41983-022-00485-7","article-title":"Predominant domains and associated demographic and clinical characteristics in multiple sclerosis-related cognitive impairment in mildly disabled patients","volume":"58","author":"Talebi","year":"2022","journal-title":"Egypt. J. Neurol. Psychiatr. Neurosurg."},{"issue":"13","key":"10.1016\/j.msard.2024.105530_bib0055","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458514533162","article-title":"An adverse lipid profile is associated with disability and progression in disability, in people with MS","volume":"20","author":"Tettey","year":"2014","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105530_bib0056","series-title":"Joanna Briggs Institute Reviewer's Manual","first-page":"3","article-title":"Systematic reviews of effectiveness","author":"Tufanaru","year":"2017"},{"issue":"2","key":"10.1016\/j.msard.2024.105530_bib0057","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1194\/jlr.M072751","article-title":"Serum lipid profile changes predict neurodegeneration in interferon-\u03b21a-treated multiple sclerosis patients","volume":"58","author":"Uher","year":"2017","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.msard.2024.105530_bib0058","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1007\/s00415-022-11072-4","article-title":"Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies","volume":"269","author":"Vandebergh","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105530_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105020","article-title":"Dysregulation of humoral immunity, iron homeostasis, and lipid metabolism is associated with multiple sclerosis progression","volume":"79","author":"Wang","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2024.105530_bib0060","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458516635873","article-title":"Genetic overlap between multiple sclerosis and several cardiovascular disease risk factors","volume":"22","author":"Wang","year":"2016","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0061","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1742-2094-8-127","article-title":"Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis","volume":"8","author":"Weinstock-Guttman","year":"2011","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2024.105530_bib0062","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12974-022-02502-1","article-title":"Fatty acids role in multiple sclerosis as \"metabokines\"","volume":"19","author":"Yu","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2024.105530_bib0063","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/acn3.51516","article-title":"Lipid levels and the risk of dementia: a dose\u2013response meta-analysis of prospective cohort studies","volume":"9","author":"Zhu","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2024.105530_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104367","article-title":"Impact of Dyslipidemia on Progression of Multiple Sclerosis","volume":"71","author":"Zoubi","year":"2023","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:40:39Z","timestamp":1738064439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":64,"alternative-id":["S2211034824001093"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105530","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum lipids and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105530"}}